Kintor
Kintor
Kintor

About Us

We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,

including alopecia, acne, prostate cancer, liver cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Picture Name

Small-molecule drugs

Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics

Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

Combination therapies

To provide the best treatment for prostate and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

Picture Name

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a……

Picture Name
Picture Name

Manufacturing base

 Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing bas……

Picture Name
Picture Name

Business operation

 In anticipation of the commercial launch of our products, Kintor……

Picture Name

News Center

2026-11-03

Completion of Long-term Safety Clinical Trial of KX-826 Tincture 1.0% For The Treatment of Male Adult AGA in China

Suzhou, 3 November, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term safety clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of androgenetic alopecia has completed follow-up visits for the subjects, demonstrating favorable safety.
Picture Name

2026-10-21

Receipt of Notice of Grant of Invention Patent For KT-939

Suzhou, 21 October, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Group received a notice of grant of invention patent issued by the China National Intellectual Property Administration in respect of KT-939 (Chinese trade name 欧希美多®KT-939, English trade name OXIMIDOL®KT-939), a novel and highly effective tyrosinase inhibitor developed in-house by the Group for inhibiting melanin production. The patent relates to a tyrosinase inhibitor and uses thereof (application No. 202580002670.3).
Picture Name

2026-09-07

Successful Completion of Long-Term Human Safety Trial Of KT-939

Suzhou, 7 September, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term human safety trial of KT-939, an in-house developed novel and highly effective tyrosinase inhibitor for inhibiting melanin production, was successfully completed on 4 September 2026. A total of 114 subjects received continuous administration of KT-939 for 52 consecutive weeks, and preliminary data indicate that none of them experienced any adverse skin reactions, in line with the 28 week interim clinical results, fully demonstrating the excellent safety profile of KT-939.
Picture Name
View more
Picture Name

Work at Kintor

We're developing new products to improve human health,and we're looking for people like you to help shape the future at Kintor Pharmaceuticals.We're building a company based on curiosity, talent, and intellectual capital. We provide employees with opportunities for career development and personal growth.lf you're interested  in joining our team, please send your CV to kintor- HR@kintor. com. cn.

Join Us

Kintor